Danaher Corporation (DHR)
| Market Cap | 176.31B |
| Revenue (ttm) | 23.74B |
| Net Income (ttm) | 3.89B |
| Shares Out | 722.28M |
| EPS (ttm) | 5.24 |
| PE Ratio | 46.55 |
| Forward PE | 30.79 |
| Dividend | $1.08 (0.44%) |
| Ex-Dividend Date | Dec 27, 2024 |
| Volume | 2,323,415 |
| Open | 239.95 |
| Previous Close | 238.36 |
| Day's Range | 239.00 - 244.49 |
| 52-Week Range | 225.42 - 281.70 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 285.94 (+17.14%) |
| Earnings Date | Jan 29, 2025 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and service... [Read more]
Financial Performance
In 2023, Danaher's revenue was $23.89 billion, a decrease of -10.33% compared to the previous year's $26.64 billion. Earnings were $4.74 billion, a decrease of -33.23%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for DHR stock is "Buy." The 12-month stock price forecast is $285.94, which is an increase of 17.14% from the latest price.
News
3 Top Blue-Chip Stocks to Buy and Hold for 2025
#Morningstar #BestStockstoBuyNow #BlueChipStocks The undervalued stocks of these reliable large companies look attractive today. 00:00 Introduction 00:43 Microsoft MSFT 01:29 Pepsi PEP 02:16 Danaher D...
Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications
FARGO, N.D.--(BUSINESS WIRE)--Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications.
Danaher: Transition Year Recap
Danaher faced a disappointing 2024, despite beating Q3 expectations, due to unaltered full-year guidance and a significant asset writedown. The company executed a $4.5 billion share buyback, with an a...
The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems
In a challenging market marked by uncertainty, building a resilient portfolio is key to long-term financial stability and peace of mind. Sleep-well-at-night, or SWAN, stocks are key. These reliable di...
Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research
New, Fully Automated, High-Throughput RUO Assays offered on Beckman Coulter Immunoassay Analyzers BREA, Calif. , Jan. 15, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in advanced ...
Danaher Corporation (DHR) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Danaher Corporation (NYSE:DHR) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2024 2:15 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Part...
Danaher CEO to Comment on Financial Performance
WASHINGTON , Jan. 13, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Compa...
Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth
Seeking Alpha's Quant Valuation and Growth Grades identify 6 blue-chip stocks with extremely high valuations matched against limited operating growth potential. Costco, Cencora, West Pharmaceutical Se...
Danaher Announces Investment Partnership in Innovaccer Inc.
Partnership seeks to improve patient outcomes and experience through novel digital and diagnostic solutions. Investment aligns with Danaher's mission to accelerate the transition to precision medicine...
Danaher to Present at J.P. Morgan Healthcare Conference
WASHINGTON , Jan. 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.
Danaher: A Wide-Moat Gem I Cannot Buy Enough Of
Danaher boasts a wide-moat business model with mission-critical products and recurring revenue streams, ensuring a durable competitive advantage and long-term growth potential. The company's disciplin...
Danaher Schedules Fourth Quarter 2024 Earnings Conference Call
WASHINGTON , Jan. 2, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2024 on Wednesday, January 29, 20...
3 of the Best Companies to Own in 2025 and Beyond
#Morningstar #BestStockstoInvestIn #StockInvesting These companies have durable competitive advantages and generate reliable cash flows. 00:00 Introduction 00:46 Danaher DHR 01:36 Paychex PAYX 02:17 ...
Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value
Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "M...
Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst
BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024.
Danaher Announces Quarterly Dividend
WASHINGTON , Dec. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common s...
Danaher: A Resilient And Solid Company With Growth Potential
Danaher has maintained a net earning margin above 15% since 2017. In 2024 Q3, the company had a 36.36% liabilities-to-assets ratio, the lowest level since 2017. Danaher's largest customers have reduce...
Danaher Corporation (DHR) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Danaher Corporation (NYSE:DHR) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 3:25 PM ET Company Participants Rainer Blair - President and CEO Conference Call Participants Vija...
Danaher to Present at Evercore ISI HealthCONx Conference
WASHINGTON , Nov. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conf...
Revving Up: 2 Underperforming Dividend Giants Ready To Outshine
Two high-quality dividend stocks are finally positioned for a strong rebound. After a period of underperformance, their growth potential is back in focus. These companies have adapted well to recent c...
Understanding Danaher's Cautiousness
Danaher reported okay Q3 earnings, with "cautiousness" probably being the best adjective to describe the release. The company has finally returned to growth and forward-looking commentary seems positi...
Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating
On Tuesday, Danaher Corp DHR reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the consensus of $5.59 billion.
Danaher Corporation (DHR) Q3 2024 Earnings Call Transcript
Danaher Corporation (NYSE:DHR) Q3 2024 Earnings Call Transcript October 22, 2024 8:00 AM ET Company Participants John Bedford - VP of IR Rainer Blair - President and CEO Matt McGrew - EVP and CFO Con...
Danaher beats quarterly profit estimates on strong demand for bioprocessing unit
Danaher on Tuesday beat Wall Street estimates for third-quarter profit on strong demand for its diagnostics and bioprocessing businesses, alongside growth in its molecular testing unit.